As less invasive therapies, such as GLP-1 receptor agonists, are increasingly used worldwide to treat obesity and associated diseases, it would also be of interest if ACBP/DBI might act in this setting as a potential biomarker. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.